Novo Nordisk Market Vaps KRW 97 Trillion in a Day...GLP1 family obesity drug growth slowdown signal?
Jul 30, 2025
|
Novo Nordisk also announced that it lowered its previous full-year sales growth forecast from 13-21% to 8-14% and its operating profit growth forecast from 16-24% to 10-16% as well. The move is based on the judgment that the pace of high-cost sales in the U.S. will slow down due to the launch of new products by competitors such as Eli Lilly and intensifying competition for generic drugs. Novo Nordisk's stock price decline this year is 44%, which once lowered its outlook for this year due to poor first-quarter performance in May.
Novo Nordisk announced on the same day that it would appoint Majir Mike Dusdar, vice president of its international business division, as its new CEO, but the market's response was not cool.
Novo Nordisk, which has grown into the most valuable listed company in Europe since the launch of the GLP-1 (Glucagon-like peptide-1)-based obesity treatment WeGovi in 2021, has seen its growth slow down due to the recent large number of 'combination medicines'.
Meanwhile, attention is being paid to whether such a decline in Novo Nordisk's stock price will lead to a slump in the related market. Not only Novo Nordisk but also Eli Lilly's stock price fell by about 5.6% on the New York Stock Exchange, and some analysts say it is a sign of slowing overall growth of GLP-1 diet drugs. Furthermore, there are concerns that Novo Nordisk's stock price plunge could dampen investor sentiment in the global bio and pharmaceutical industries.
This article was translated by Naver AI translator.
